ViroLogic
This article was originally published in The Gray Sheet
Executive Summary
South San Francisco, Calif.-based biotechnology firm launches PhenoSense GT HIV drug resistance test Nov. 15. The test, which integrates ViroLogic's phenotypic assay PhenoSense HIV with the firm's genotypic assay GeneSeq HIV, is the "first HIV drug resistance test to provide doctors with a single report on a patient's drug resistance profile using phenotypic test results supplemented by genotypic information," according to the firm...